[go: up one dir, main page]

AR067056A1 - Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento - Google Patents

Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento

Info

Publication number
AR067056A1
AR067056A1 ARP080102605A ARP080102605A AR067056A1 AR 067056 A1 AR067056 A1 AR 067056A1 AR P080102605 A ARP080102605 A AR P080102605A AR P080102605 A ARP080102605 A AR P080102605A AR 067056 A1 AR067056 A1 AR 067056A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
alkoxy
hydroxy
compound
Prior art date
Application number
ARP080102605A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR067056A1 publication Critical patent/AR067056A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de espiroindolina de la siguiente formula (1), o una de sus sales farmacéuticamente aceptable o uno de sus enantiomeros; en la que cada R1 es independientemente halogeno, CF3, alquilo C1-4, alcoxi C1-4, OCF3, CN, alquil C1-6-C(O)-NH-, alquil C1-6NH-C(O)-, -CH2-N(R7)2, -CH2-O-R8, C1-4S(O)r-, COOH o heteroarilo; R2 es H, alquilo C1-4, -CH2C(O)OR9 o CH2C(O)N(R9)2; cada R3 es independientemente alquilo C1-6 o hidroxi-alquilo C1-6 cada R4 es independientemente OH, F, CI, CN, alquilo C1-4, hidroxi-alquilo C1-4, o alcoxi C1-4, Y es-NH-o como el resto de formula (2); R5 es H, OH, F, CI, CN, CF3, alquilo C1-6, hidroxi-alquilo C1-6 o alcoxi C1-6; cada R6 es independientemente halogeno, CF3, alquilo C1-4, alcoxi C1-4, OCF3, benciloxi o CN; cada R7 es independientemente H, alquilo C1-4 o junto con el átomo de nitrogeno al que están unidos, forman un grupo heterocicloalquilo de 5 o 6 miembros; R8 es H, alquilo C1-6, bencilo o fenilo; cada R9 es independientemente H, alquilo C1-6 o bencilo; cada R10 es independientemente OH, F, CI, CN, alquilo C1-4, hidroxi-alquilo C1-4 o alcoxi C1-4, n es 0, 1 o 2; m es 0, 1, 2 o 3; p es 0, 1 o2; q es 0, 1 o2; r es 0, 1 o 2; y s es 0, 1 o 2. La sal de benzoato de dicho compuesto. Composicion que lo comprende y uso de dicho compuesto para preparar un medicamento util para el tratamiento de enfermedades asociadas con la sobreexpresion de CCR2, tales como aterosclerosis, dolor inflamatorio, influenza, síndrome metabolico, esclerosis multiple, asma, enfermedad renal, insuficiencia cardiaca congestiva, enfermedad de Alzheimer, accidente cerebrovascular, enfermedad de Crohn, enfermedad inflamatoria del intestino, endometriosis o diabetes.
ARP080102605A 2007-06-20 2008-06-19 Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento AR067056A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94514707P 2007-06-20 2007-06-20
US4315608P 2008-04-08 2008-04-08

Publications (1)

Publication Number Publication Date
AR067056A1 true AR067056A1 (es) 2009-09-30

Family

ID=40137143

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102605A AR067056A1 (es) 2007-06-20 2008-06-19 Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento

Country Status (9)

Country Link
US (2) US7723350B2 (es)
EP (1) EP2166848A4 (es)
JP (1) JP5341076B2 (es)
AR (1) AR067056A1 (es)
CL (1) CL2008001810A1 (es)
PE (1) PE20090829A1 (es)
TW (1) TW200904423A (es)
UY (1) UY31162A1 (es)
WO (1) WO2008157741A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015708B (zh) * 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
EP2370423A4 (en) * 2008-12-04 2012-05-30 Glaxo Group Ltd PROCESS FOR PREPARING A SPIROINDOLINE AND A PREVENT Therefor
WO2010093578A1 (en) * 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
US8563722B2 (en) 2009-02-24 2013-10-22 Glaxo Group Limited Stereoselective hydrogenation of a ketone
AU2011212478B2 (en) 2010-02-05 2014-11-06 Intervet International B.V. Spiroindoline Compounds For Use as Anthelminthics
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds
US10503774B2 (en) * 2012-01-27 2019-12-10 Koninklijke Philips N.V. Medical selection system
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
EP3570893A1 (en) 2017-01-17 2019-11-27 GlaxoSmithKline Intellectual Property Development Ltd Non peptidic heterobivalent molecules for treating inflammatory diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2278309A1 (en) * 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
GB0107907D0 (en) * 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
WO2004041279A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
CA2546147A1 (en) * 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
EP1802602A1 (en) * 2004-09-28 2007-07-04 Janssen Pharmaceutica N.V. Substituted dipiperdine ccr2 antagonists
CN101227903A (zh) 2005-06-02 2008-07-23 詹森药业有限公司 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物
US20070197590A1 (en) * 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
EP2190286A4 (en) * 2007-08-14 2011-06-01 Glaxo Group Ltd SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS
JP2011500590A (ja) * 2007-10-11 2011-01-06 グラクソ グループ リミテッド ケモカイン受容体のモジュレータとしてのピペリジニルヒドロキシエチルピペリジン誘導体
WO2009061881A1 (en) 2007-11-07 2009-05-14 Glaxo Group Limited Spirodihydrobenzofurans as modulators of chemokine receptors
ES2414159T3 (es) * 2008-06-23 2013-07-18 Janssen Pharmaceutica, N.V. Antagonistas de acrilamida piperidilo de CCR2

Also Published As

Publication number Publication date
EP2166848A4 (en) 2011-08-03
JP5341076B2 (ja) 2013-11-13
US20080318990A1 (en) 2008-12-25
JP2010530886A (ja) 2010-09-16
CL2008001810A1 (es) 2008-12-26
UY31162A1 (es) 2008-11-28
PE20090829A1 (es) 2009-07-25
EP2166848A1 (en) 2010-03-31
US20110034499A1 (en) 2011-02-10
WO2008157741A1 (en) 2008-12-24
US7723350B2 (en) 2010-05-25
TW200904423A (en) 2009-02-01
US8431590B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
AR067056A1 (es) Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
AR079260A1 (es) Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
PE20090159A1 (es) COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
ME02766B (me) Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
HRP20171028T1 (hr) Indolski i indazolski spojevi koji aktiviraju ampk
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep
MY169986A (en) Benzimidazole-proline derivatives
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
PE20080281A1 (es) COMPUESTOS CINAMIDA COMO INHIBIDORES DE LA SINTESIS DEL ß-AMILOIDE 40 Y 42
JP2016506935A5 (es)
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR058065A1 (es) Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
BR112015006436A2 (pt) novas piridinonas bicíclicas
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure